melatonin has been researched along with Down Syndrome in 11 studies
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Down syndrome (DS) is a disorder characterised by marked immune dysfunction, increased mortality from sepsis, chronic inflammation, increased oxidative stress, sleep disturbance and possibly abnormal endogenous melatonin levels." | 8.12 | Melatonin as an immunomodulator in children with Down syndrome. ( Balfe, J; Doherty, DG; Fallah, L; Gallagher, E; Huggard, D; Kelly, L; Lagan, N; McGrane, F; Molloy, EJ; Roche, E; Worrall, A; Yoo, LL, 2022) |
| "Melatonin administered during adulthood induces beneficial effects on cognition and neuroprotection in the Ts65Dn (TS) mouse model of Down syndrome." | 7.85 | Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Diego, M; García-Cerro, S; Lantigua, S; Martínez-Cué, C; Parisotto, EB; Rueda, N; Sanchez-Barceló, EJ; Vidal, V; Wilhem Filho, D, 2017) |
| "Previous studies have demonstrated that melatonin administration improves spatial learning and memory and hippocampal long-term potentiation in the adult Ts65Dn (TS) mouse, a model of Down syndrome (DS)." | 7.83 | Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome. ( García-Cerro, S; Lantigua, S; Martínez-Cué, C; Parisotto, EB; Rueda, N; Sanchez-Barceló, EJ; Vidal, V; Wilhelm Filho, D, 2016) |
| "Melatonin treatment improved spatial learning and memory and increased the number of choline acetyltransferase (ChAT)-positive cells in the medial septum of both TS and CO mice." | 5.39 | Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. ( Corrales, A; Flórez, J; García, E; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sanchez-Barceló, EJ; Vidal, V, 2013) |
| "Down syndrome (DS) is a disorder characterised by marked immune dysfunction, increased mortality from sepsis, chronic inflammation, increased oxidative stress, sleep disturbance and possibly abnormal endogenous melatonin levels." | 4.12 | Melatonin as an immunomodulator in children with Down syndrome. ( Balfe, J; Doherty, DG; Fallah, L; Gallagher, E; Huggard, D; Kelly, L; Lagan, N; McGrane, F; Molloy, EJ; Roche, E; Worrall, A; Yoo, LL, 2022) |
| "Melatonin could represent a useful clinical adjunct in the treatment of sepsis as an immunomodulator." | 3.88 | Altered endotoxin responsiveness in healthy children with Down syndrome. ( Balfe, J; Doherty, DG; Franklin, O; Huggard, D; Lagan, N; Leahy, TR; McGrane, F; Melo, AM; Molloy, EJ; Moreno, A; Roche, E, 2018) |
| "Melatonin administered during adulthood induces beneficial effects on cognition and neuroprotection in the Ts65Dn (TS) mouse model of Down syndrome." | 3.85 | Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Diego, M; García-Cerro, S; Lantigua, S; Martínez-Cué, C; Parisotto, EB; Rueda, N; Sanchez-Barceló, EJ; Vidal, V; Wilhem Filho, D, 2017) |
| "Previous studies have demonstrated that melatonin administration improves spatial learning and memory and hippocampal long-term potentiation in the adult Ts65Dn (TS) mouse, a model of Down syndrome (DS)." | 3.83 | Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome. ( García-Cerro, S; Lantigua, S; Martínez-Cué, C; Parisotto, EB; Rueda, N; Sanchez-Barceló, EJ; Vidal, V; Wilhelm Filho, D, 2016) |
| "The present results suggest that sleep fragmentation and any resultant cognitive deficits are likely not confounded by corresponding deficits in circadian rhythms." | 1.46 | Young children with Down syndrome show normal development of circadian rhythms, but poor sleep efficiency: a cross-sectional study across the first 60 months of life. ( Anand, P; Clark, C; Demara, BI; Edgin, JO; Fernandez, F; Nyhuis, CC; Ruby, NF; Spanò, G, 2017) |
| "Melatonin treatment improved spatial learning and memory and increased the number of choline acetyltransferase (ChAT)-positive cells in the medial septum of both TS and CO mice." | 1.39 | Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. ( Corrales, A; Flórez, J; García, E; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sanchez-Barceló, EJ; Vidal, V, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Huggard, D | 2 |
| Kelly, L | 1 |
| Worrall, A | 1 |
| Gallagher, E | 1 |
| Fallah, L | 1 |
| Yoo, LL | 1 |
| McGrane, F | 2 |
| Lagan, N | 2 |
| Roche, E | 2 |
| Balfe, J | 2 |
| Doherty, DG | 2 |
| Molloy, EJ | 2 |
| Fernandez, F | 1 |
| Nyhuis, CC | 1 |
| Anand, P | 1 |
| Demara, BI | 1 |
| Ruby, NF | 1 |
| Spanò, G | 1 |
| Clark, C | 1 |
| Edgin, JO | 1 |
| Corrales, A | 3 |
| Parisotto, EB | 2 |
| Vidal, V | 4 |
| García-Cerro, S | 2 |
| Lantigua, S | 2 |
| Diego, M | 1 |
| Wilhem Filho, D | 1 |
| Sanchez-Barceló, EJ | 4 |
| Martínez-Cué, C | 4 |
| Rueda, N | 4 |
| Leahy, TR | 1 |
| Franklin, O | 1 |
| Moreno, A | 1 |
| Melo, AM | 1 |
| Vidal, R | 1 |
| García, S | 2 |
| Martínez, P | 2 |
| García, E | 2 |
| Flórez, J | 2 |
| Wilhelm Filho, D | 1 |
| Uberos, J | 1 |
| Romero, J | 1 |
| Molina-Carballo, A | 1 |
| Muñoz-Hoyos, A | 1 |
| Arruda, MA | 1 |
| Bonamico, L | 1 |
| Stella, C | 1 |
| Bordini, CA | 1 |
| Bigal, ME | 1 |
| Pierpaoli, W | 1 |
| Lesnikov, VA | 1 |
| Reiter, RJ | 1 |
| Barlow-Walden, L | 1 |
| Poeggeler, B | 1 |
| Heiden, SM | 1 |
| Clayton, RJ | 1 |
1 review available for melatonin and Down Syndrome
| Article | Year |
|---|---|
The pineal aging clock. Evidence, models, mechanisms, interventions.
Topics: Aging; Animals; Biological Clocks; Body Temperature Regulation; Child, Preschool; Down Syndrome; Hum | 1994 |
10 other studies available for melatonin and Down Syndrome
| Article | Year |
|---|---|
Melatonin as an immunomodulator in children with Down syndrome.
Topics: Anti-Inflammatory Agents; Child; Cytokines; Down Syndrome; Humans; Immunologic Factors; Inflammasome | 2022 |
Young children with Down syndrome show normal development of circadian rhythms, but poor sleep efficiency: a cross-sectional study across the first 60 months of life.
Topics: Actigraphy; Child; Child, Preschool; Circadian Rhythm; Cross-Sectional Studies; Down Syndrome; Femal | 2017 |
Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Animals, Newborn; Brain; Catalase; Cell Proliferation; Cognition; Conditioning, Psychologic | 2017 |
Altered endotoxin responsiveness in healthy children with Down syndrome.
Topics: CD11b Antigen; Child; Child, Preschool; Down Syndrome; Escherichia coli; Female; Humans; Immunologic | 2018 |
Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Down Syndrome; Female; Hippocampus; Indoles; | 2014 |
Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome.
Topics: Animals; Antioxidants; Cellular Senescence; Disease Models, Animal; Down Syndrome; Glutathione Perox | 2016 |
Melatonin and elimination of kynurenines in children with Down's syndrome.
Topics: Child; Child, Preschool; Circadian Rhythm; Down Syndrome; Female; Humans; Kynurenic Acid; Kynurenine | 2010 |
Cluster headache in children and adolescents: ten years of follow-up in three pediatric cases.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Child; Cluster H | 2011 |
Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome.
Topics: Administration, Oral; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Behavior, Anima | 2013 |
Twenty-four hour urinary excretion of 6-hydroxymelatonin sulfate in Down syndrome subjects.
Topics: Adolescent; Adult; Child; Child, Preschool; Circadian Rhythm; Darkness; Down Syndrome; Female; Human | 1996 |